Purpose Diets rich in plant-derived polyphenols such as olive oil (OO) and/or catechins such as epigallocatechin 3-gallate (EGCG) have been shown to reduce the incidence of cardiovascular diseases, potentially by improving endothelial function, an important surrogate for atherosclerosis. The possible augmentation of endothelial function with the combined efforts of OO and EGCG is intriguing, yet unknown. Methods Eighty-two patients with early atherosclerosis (presence of endothelial dysfunction) were enrolled in this double-blind, randomized trial with 52 completing the study. The aim of the study was to compare the effect of a daily intake of 30 ml simple OO, with 30 ml of EGCG-supplemented OO, on endothelial function as well as on inflammation and oxidative stress after a period of 4 months. Endothelial function was assessed noninvasively via peripheral arterial tonometry (Endo-PAT Ò ). Results After 4 months, when OO and EGCG-supplemented OO groups were combined, OO significantly improved endothelial function (RHI, 1.59 ± 0.25-1.75 ± 0.45; p \ 0.05). However, there were no significant differences in results between the two olive oil groups. Interestingly, with OO supplementation there was a significant reduction in inflammatory parameters: sICAM (196 to 183 ng/mL, p = \ 0.001); white blood cells (WBCs) (6.0 9
Introduction
Olive oil is an important source of polyphenols in the Mediterranean diet [11] . Consumption of diets rich in polyphenols has been shown to enhance nitric oxide (NO) bioavailability as well as decrease oxidative stress and inflammation [2, 14, 29] . Recent randomized trials have pointed out the important antioxidant effect of extra virgin olive oil (OO) in humans [6, 33] . The Italian Virgin Olive Oil Study [33] demonstrated a significant decrease in total antioxidative capacity (and platelet activation) in mildly dyslipidemic patients. This trial studied the effects of extra virgin OO compared to highly refined olive oil, which is much lower in polyphenols. The Eurolive study [6] , a randomized trial, showed a linear decrease in markers of oxidative stress with increasing polyphenolic content of the olive oils.
Epigallocatechin 3-gallate (EGCG) is a green tea-derived phenol that has been described as a biologically potent fraction of the polyphenol family and is thought to be the active ingredient in green tea [1, 5] . OO and EGCG might potentiate antioxidant power when combined; however, the effects on cardiovascular health of dietary supplementation with either olive oil alone or in combination with EGCG are unknown.
Endothelial dysfunction is regarded as an early stage of atherosclerosis leading to subsequent cardiovascular morbidity and mortality [4] . Endothelial dysfunction is associated with most cardiovascular risk factors and is an independent predictor of cardiovascular events [18] . Recently, studies showed conflicting results of the effect of olive oil on endothelial function, potentially because of the low polyphenol content and the brief period of OO ingestion [15, 28, 31] .
Definitive evidence regarding the effect of long-term (4 month) supplementation with OO on endothelial function is lacking. Additionally, there are no data regarding the effect of long-term OO and/or EGCG supplementation on endothelial function.
The aim of our study was to demonstrate the effect of OO on endothelial function over the long term (4 month), and to study whether OO with additional EGCG is more effective than OO alone in augmenting endothelial function and surrogate markers for cardiovascular disease. Thus, we utilized a double-blind, randomized controlled study to compare the effect of 4-month supplementation of OO versus EGCG-enriched OO (OO ? EGCG) on endothelial function, as well as on oxidative stress and inflammation in patients with low to intermediate cardiovascular risk.
Methods

Study population
Subjects over the age of 18 years were enrolled regardless of previous history of cardiovascular events. Patients were recruited from the Division of Cardiovascular Diseases at Mayo Clinic in Rochester, MN (ClinicalTrials.gov Identifier: NCT00865787), as well as by intra-institutional advertising seeking research participants. Participants underwent endothelial function testing with the EndoPAT Ò device. Those with normal EndoPAT Ò score ([2.0) and/or uncontrolled hypertension (blood pressure, [180/100) were excluded from the study. Other exclusion criteria were history of renal or liver failure and relevant food allergies. Informed consent was obtained and signed by all participants.
Experimental protocol
This was a controlled, randomized double-blind study conducted in accordance with the ethical standards of the responsible institutional or regional committee on human experimentation or in accordance with the Helsinki Declaration of 1975 as revised in 1983 and in accordance with the policies and procedures of the local ethics committee and Mayo Clinic Institutional Review Board. Participants were instructed not to change their diets despite olive oil supplementation and were not given any special dietary instructions so as to have olive oil as the sole added variable in their diet. Details are in Fig. 1 All participants were instructed to fast for at least 4 h prior to each appointment and to abstain from caffeine and tobacco products for 24 h. In addition, participants were instructed to hold ACE inhibitors and calcium channel blockers for 24 h, and nitrates for 6 h prior to the appointment. Examinations were performed in the morning. During a short clinical examination, blood pressure, body weight, and body height were obtained. EndoPAT Ò testing was performed. Participants were then randomized to receive a once-daily serving of 30 mL of either EGCGcontaining OO or OO alone for a total duration of 4 months. Participants were instructed to consume a single dose of the uncooked study product during one of their daily meals so as to simplify the regimen and ensure a total of 30 mL OO taken daily. Measurements were repeated after 4 months to assess long-term effects. Participants were also contacted by phone at 1 and 3 months to assess compliance and any changes in medications or symptoms.
Endothelial function assessment
Studies were performed in a designated quiet, temperaturecontrolled, and uniformly lit room. EndoPAT Ò signals were obtained using the Endo-PAT Ò 2000 device (Itamar Medical Inc. Ltd, Caesarea, Israel.), which has been used previously by our laboratory [4, 12, 17] with a high level of reproducibility [27] . Endothelial function was measured by a reactive hyperemia-peripheral arterial tonometry (RH-PAT) as previously described [3, 4] , typically in the dominant hand of the individual unless a contraindication existed and on the arm originally used at baseline for follow-up for each returning subject. After 5-min baseline PAT recording, a blood pressure cuff was inflated on one arm to 60 mmHg (or at least 200 mmHg) above baseline systolic blood pressure for 5 min. Occlusion of pulsatile arterial flow was confirmed via the PAT tracing. After 5 min, the cuff was deflated and the PAT tracing recorded for another 6 min. The ratio (RH-PAT index) of the PAT signal after cuff release compared to baseline was calculated through a computer algorithm automatically normalizing for baseline RH-PAT signal and indexed to the contralateral arm. Reactive hyperemia responses were recorded at baseline and after the 4-month treatment period.
Blood tests
Blood measurements of lipids, inflammatory markers, and endogenous oxidative stress markers were performed at baseline and at 4 months as previously described [4] . Inflammatory markers measured included hsCRP, IL-6, soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), fibrinogen, and a complete blood count with differential. Endogenous oxidative stress markers measured included plasma 8-isoprostane and oxidized LDL (oxLDL). Standard lipid profiles (total cholesterol, triglycerides, HDL, and LDL), and lipoprotein particle subfractions by NMR (nuclear magnetic resonance) [10] spectroscopy, were also assessed at baseline and 4 months in both OO groups.
Study olive oil and polyphenols OO was supplied by Olivi Agri Team Srl (Grosseto, Italy), and the enhanced/enriched sample (OO with EGCG) was prepared according to a patent (pending, Olivi Agri Team Srl). Oleuropein, EGCG, and luteolin were purchased from Extrasynthese (Geney, France), and the OH-Tyr was purchased from Cayman Chemical (SPI-BIO, Europe). The enhanced samples were produced at IMET factory in Italy (Bergamasco, Italy). OO alone (340 mg/kg polyphenol content) and OO plus EGCG (600 mg/kg polyphenol content) were incorporated into participants' diets as previously reported [23] .
Statistical analysis
Statistical analysis was performed by an independent statistician blinded to the randomization after completion of the studies. Results are expressed as mean ± standard deviation or median with interquartile ranges if data were not normally distributed. Discrete data are presented as frequency (percentage). Differences between randomized groups were compared using Student's two-sample t test, the Wilcoxon rank sum test, or Pearson's chi-squared test, as appropriate. Among all randomized patients who had a 4-month follow-up study, differences between 4-month and baseline measures were compared using a signed rank test. A two-sample t test of the change in EndoPAT Ò score at 4 months was used to compare those with baseline scores \1.6 versus those with scores C1.6 to delineate. Statistical significance was accepted at p \ 0.05. OO groups, with and without EGCG, were analyzed separately and also subsequently pooled as part of a subgroup analysis. These were compared using a two-way ANOVA between and among groups. Additionally, these patients underwent the same rigorous enrollment and intake process described above.
Results
Olive oil composition
The main difference in the phenol composition of the two OOs (Table 1) is the higher content of secoiridoids in the OO (61 %) while the OO enriched with EGCG arrived up only to 48 %. At the same time, the lignans, another group of main constituents, have shown almost the same amount in the two oils.
Baseline characteristics
Eighty-two qualified subjects were randomized for the study. Of these, 52 subjects were able to complete the 4-month protocol as a majority of patients voluntarily declined to continue the study usually secondary to side effects of the OO consumption, and 50 participants had follow-up EndoPAT Ò measurements. Baseline characteristics of the OO and OO ? EGCG patients evaluated in the study are displayed in Table 2 . No significant differences between the two randomized olive oil groups were detected regarding factors such as comorbidities, medications, sex, risk factors, or other entities known to be associated with early CVD or endothelial dysfunction. Framingham risk scores were not significantly different between the two OO groups (2.0 ± 2.9 vs. 2.2 ± 3.8; p = 0.81). Comparisons of participant's medications taken prior to the study were examined and found not to be significantly different.
The effect of OO on hemodynamic data and endothelial function After 4 months of olive oil supplementation, there was no significant change in heart rate (p = 0.28), systolic (p = 0. 16) Fig. 2 ). In those patients who had poor endothelial function at baseline (RHI \1.6), there was a significant increase in EndoPAT participants, there were significant reductions in white blood cell counts (WBCs) and sICAM-1 (Tables 3 and 4) in the combined OO group after 4 months. Moreover, the cell types reduced by OO supplementation included lymphocytes, monocytes, and platelets. Neutrophils also tended to be reduced. However, these effects did not differ between the different OO treatment groups (with and without EGCG). Inflammatory and oxidative stress markers such as hsCRP, IL-6, sVCAM-1, as well as oxLDL were not affected significantly. Plasma 8-isoprostane increased with the treatment of olive oil supplementation (Tables 3 and 4) .
Serum lipoproteins
Lipid profiles did not change significantly within or between OO groups: HDL (46 mg/dL, baseline, to 51 mg/dL at four months; p = 0.79), LDL (102-105 mg/dL; p = 0.56), total cholesterol (178-178 mg/dL; p = 0.79), and triglycerides (106-103 mg/dL; p = 0.35). Lipoprotein particles measured by NMR spectroscopy also showed no significant changes in the OO groups (not reported).
Discussion
The current study demonstrates that longer-term supplementation of olive oil improves endothelial function in individuals with low to intermediate CV risk, an effect likely attributed to reduction in vascular inflammation. This is the first such demonstration of such a permanent endothelial benefit via long-term supplementation of a macronutrient. However, further enrichment with polyphenols (EGCG) does not provide any additional benefit above those attributable to olive oil alone [19, 38] . Although the main goal of the study-demonstrating the superiority of polyphenol-enriched OO-was not achieved, the study nevertheless further supports the role, and potentially ascribes some mechanisms, of the aforementioned benefit of olive oil on cardiovascular health [6, 20, 33] . A concomitant reduction in white blood cells, particularly monocytes and neutrophils, as well as sICAM points to a potential mechanism for improved endothelial function through a reduction in vascular inflammation. Interestingly, patients with low endothelial function at baseline appear to garner the most benefit from OO. Thus, supplementation with OO seems a reasonably easy and relatively cheap dietary measure to improve the endothelial function and perhaps favorably alter the progression of atherosclerotic disease, particularly in patients with already markedly impaired endothelial function. Olive oil, a major component of the Mediterranean diet, is a rich source of a variety of polyphenols. Indeed, OO has been shown to positively and acutely impact endothelial function as soon as 2 h after consumption [22] ; however, the mechanism for this improvement and the responsible ingredient has not yet clearly been identified [26] . The current study is in accord with-and expounds uponpreviously observed data and is also the first to show a sustained effect on endothelial function after long-term OO supplementation. We also show that those with baseline endothelial dysfunction benefit the greatest from OO supplementation, perhaps offering yet another treatment modality for those patients at greatest risk of future cardiac events. Because the bioavailability of plant-derived polyphenols in the blood is rather short [36] , ingredients in olive oil likely have altered the expression of certain longterm endothelial modulators, such as nitric oxide synthase, to see this sustained effect. Contrary to other studies [6, 24, 33] , we were not able to demonstrate a sustained antioxidant effect from OO supplementation as neither oxLDL nor the isoprostanes (markers of lipid peroxidation) were reduced by OO. The significant increase in the plasma 8-isoprostane within the EGCG group might also raise the concern of a possible pro-oxidant effect of EGCG as previous animal work has shown deleterious effects of highdose vitamin supplementation on myocardial perfusion and coronary endothelial function [32] . Thus, it remains likely that over-supplementation with nearly any substance may not be beneficial and may even pose greater harm to the patient. Moreover, we were unable to appreciate a significant improvement with EGCG supplementation as seen in the previous studies [36] . This, again, could be due to the possible pro-oxidant effect of EGCG negating the beneficial effects of OO alone, or the fact that long-term supplementation with both substances offers no endothelial function benefit. We observed a simultaneous reduction in WBCs and soluble cellular adhesion molecules sICAM-1, thus [21, 30, 35] . Moreover, increased leukocyte counts have been found in both smokers [16] and diabetics [37] , and reducing WBCs has been shown to be associated with endothelium-dependent vasodilatation [8, 34] . Our data indicate that CRP is not reduced with OO supplementation. Diets high in monounsaturated fats have been known to increase NO bioavailability, and it is possible that there could be further enhancement of NO-mediated vasodilation via reduction in inflammatory markers associated with WBCs. Myeloperoxidase has also been shown to interfere with tetrahydrobiopterin production and subsequent NO release, bioavailability, and mechanism of action [13, 25] . Therefore, cellular inflammatory mediators plausibly reduce production or bioavailability of NO, or the production of reactive oxygen species that interfere with the ability of tetrahydrobiopterin to aid in the production and synthesis of NO [25] . The reduced leukocytic inflammatory mediations would allow for increased NO-mediated vasodilation and improved endothelial function and could underlie the vascular endothelial improvement seen with OO. Importantly, both the OO ? EGCG and OO alone had polyphenol concentrations that were two to five times more potent than typical commercialized olive oil [6] . This could account for the lack of difference in outcomes between the two variants of OO. The high levels of polyphenols and fats (an extra 30 g of lipids ingested daily by the patients) could also explain the high levels of isoprostanes, as the overabundance of OO could have reached the levels that caused an increase in oxidative stress. Notably, however, the participants did not gain weight with the additional daily caloric intake of the olive oil. Nevertheless, there could be a target level of polyphenols in certain foods such as olive oil that provide maximum cardiovascular benefit without side effects.
Our study did have limitations that must be taken into account. One limitation involved the lack of a control group. As OO supplementation is already known to improve endothelial function (as is green tea, of which the active ingredient is EGCG), we used OO alone as the ''control'' group. While this could be seen as a weakness, repeated and recent work has demonstrated that the ''control'' group has no change in endothelial function [7, 9] . Regardless, the addition of a ''control'' group would have no bearing on the fact that there was no further improvement with the addition of EGCG. Also, noted was the attrition of the subjects, albeit evenly divided, in this study mainly due to gastrointestinal discomfort and inability to incorporate the uncooked study product into their daily diet. Coupling with this, our study, while an RCT over an extended period of time, was limited in patient size and diversity somewhat limiting generalizability yet augmenting internal validity. Another limitation involves not measuring polyphenol plasma concentration, introducing the possibility that our supplementation did not achieve therapeutic concentrations. However, there were no statistical differences in fasting plasma glucose levels between the OO groups. Also of note, our sample population was of low to intermediate risk (mean Framingham 10-year risk percentage between 0.5 and 4 %); thus, we were examining primary prevention characteristics. Had we examined secondary prevention or a higher risk population, we might have seen further improvement in endothelial function, inflammatory markers, lipids, and WBCs.
In conclusion, OO supplementation in patients with low to intermediate risk improves endothelial function through mechanisms possibly related to improvements in inflammation. We did not observe any additive benefit of EGCG, the main component of green tea. Therefore, olive oil supplementation may be beneficial for most individuals and might theoretically reduce cardiovascular events. These benefits are consistent with the prominent role of olive oil in the Mediterranean diet.
